SCHEMBL26599052

SCHEMBL26599052

O=C(c1cccc(Cl)c1F)C1CCC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 2/20 0.46
P2RX7 Q99572 1/20 0.45
HSD11B1 P28845 1/20 0.43
MGLL Q99685 3/20 0.42
TSHR P16473 2/20 0.42
HPGD P15428 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KAT6A Q92794 1/20 0.41
HTR1F P30939 2/20 0.40
CHRM1 P11229 1/20 0.40
GAA P10253 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30606587 1.00 KDM2B (0.46) KDM2BP2RX7HSD11B1MGLLTSHR
SCHEMBL4755192 0.84 SLC6A2 (0.49) P2RX7TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL32674514 0.82 KDM2B (0.57) KDM2BHSD11B1MGLLTSHRHPGD
SCHEMBL4755206 0.80 POLB (0.52) KDM2BGAAKMT2APOLB
SCHEMBL5318682 0.78 KDM2B (0.49) KDM2BHSD11B1TSHRGAAKMT2A
SCHEMBL3389632 0.78 KDM2B (0.57) KDM2BHSD11B1MGLLTSHRHPGD
SCHEMBL1741628 0.77 P2RX7 (0.71) P2RX7HPGDKAT6ATAS1R3TAS1R1
SCHEMBL717435 0.77 CES2 (0.52) HSD11B1MGLLHPGDGAAKMT2A
SCHEMBL2642312 0.77 CES2 (0.59) HSD11B1MGLLHPGDKAT6AHTR1F
SCHEMBL11679259 0.77 HPGD (0.57) KDM2BHSD11B1MGLLTSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339402-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2025-11-06 US disclosed
EP-4511355-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FundaMental Pharma GmbH (DE) 2025-02-26 EP disclosed
WO-2024223617-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2024-10-31 WO disclosed
WO-2023203254-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2023-10-26 WO disclosed
WO-2023203254-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339402-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY TRPM4, GRM4, GRIN1 KDM2B 2281/4885P2RX7 549/4885HSD11B1 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.